In addition, compared with the typical B7-H1 blocking antibody, the antitumor effect of B7-H1 antibodies that are able to activate p38 MAPK is compromised due to the elimination of B7-H1 tumor-responsive CD8 T cells through the p38 MAPK pathway. This evidence concerns the gene CD8A and neoplasm.